Preparation and pre-vivo evaluation of no-carrier-added, carrier-added and cross-complexed [68Ga]-EDTMP formulations

PurposeThe present study aimed to develop convenient preparation and quality control protocols for [68Ga]-EDTMP, a potential radiotracer for skeletal PET imaging. Furthermore, bone binding characteristics with special focus on the influence of carrier addition were evaluated.MethodsNo-carrier-added (nca), carrier-added and novel cross-complexed [68Ga]-EDTMP formulations were prepared using [68Ga]-gallium chloride and a commercial EDTMP kit. Respective bone binding characteristics were determined on the basis of an established in-vitro method using hydroxyapatite and human bone powders as binding matrices.ResultsPre-vivo evaluation of nca [68Ga]-EDTMP yielded irreversible binding on the mineral bone phase characterised by fast binding kinetics. Generally, nca [68Ga]-EDTMP showed low uptake values comparable to nca [99mTc]-EDTMP. Interestingly, the bone binding affinity of [68Ga]-EDTMP could be increased by the addition of carriers, presumably by changing the complex structure.ConclusionsThis fast and reliable preparation protocol could enable small PET facilities without onsite cyclotron to perform PET bone scans. A comparison of all cross-complexed [68Ga]-EDTMP preparations further strengthens the recently presented “foreign carrier theory”, which highlights carrier addition as a factor strongly affecting bone uptake of radiolabelled polyphosphonates. The clinical applicability of [68Ga]-EDTMP – particularly with respect to lesion specificity and sensitivity – should be clarified in forthcoming in-vivo studies.